Last reviewed · How we verify

Blood clot and simple suture

Fundación Eduardo Anitua · Phase 3 active Small molecule

This is a biological hemostatic product that combines blood clotting factors with a suture material to promote wound healing and hemostasis.

This is a biological hemostatic product that combines blood clotting factors with a suture material to promote wound healing and hemostasis. Used for Surgical hemostasis and wound closure.

At a glance

Generic nameBlood clot and simple suture
SponsorFundación Eduardo Anitua
ModalitySmall molecule
Therapeutic areaSurgery/Wound Healing
PhasePhase 3

Mechanism of action

The product appears to be a composite hemostatic device that leverages autologous or allogeneic blood clotting components integrated with suture material to facilitate coagulation and tissue approximation at the wound site. This combination approach aims to enhance both hemostasis and structural wound support during surgical procedures.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: